Have they gone the way of Helicos?
-
-
Too early to say. They could be just re-positioning the emphasis of their workforce. But paring down the work force of a supposedly growing company is rarely a good sign. Glad I didn't apply for any of those numerous PacBio posts in the "Industry Jobs" section. :-) -
Many are supposed to be in the "R&D" section, which is probably not good news either.Comment
-
They did go on a gangbuster hiring spree prior to their IPO, and are probably discovering that the revenue cannot support the workforce expansion. With their main strength relative to the competition being long segment reads, it is a valid question to ask whether there is a sustainable commercial position there. After all, how much denovo sequencing is needed on a large scale? On the surface GNOM would appear to be targeting a more sustainable commercial target. Thoughts?Comment
-
Tumors contain complex mixtures of cell populations that evolve in response to treatment and host-specific factors. Tissue biopsies provide only static snapshots of a tumor’s state. But what if we could follow that evolution over time using a minimally invasive technique?
Liquid biopsies can detect tumor-derived material circulating in the bloodstream, providing a way to study treatment response, detect emerging resistance, and discover new biomarkers. Circulating...10-14-2026, 09:55 AM -
Researchers using sequencing and genomics tools often have to make trade-offs. They can choose between speed or scale, short reads or long-range information, or targeted panels or a view of the whole transcriptome. New technologies that have been released this year are built to address those tough choices.
We asked six companies the same four questions to learn about their latest products. The new technologies bring a lot to the table, including rethinking sequencing...
Comment